PCRXPacira BioSciences, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but well above its own median P/E.
Priced for a decline (~−7% a year). The price demands less than its three-year revenue growth of 4% a year, expectations look modest.
Expensive vs its own history: P/E 104.0 vs a 60.4 median over 18 quarters (+72% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PCRX's price assumes
Pacira BioSciences, Inc. trades at 104× earnings against 19.6× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.6 · 5.30× the median: the market pays up for this one
- Price / sales
- 1.21
Price / sales · as of 2026-Q1
- Free cash flow yield
- 13%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −6.8%
Growth the price implies · The price pays for −6.8% free cash flow growth a year for a decade; the business has delivered +12% a year over the last three.
Details›
- Price / bookas of 2026-Q1
- 1.36
- EV / EBIToperating margin 2.7%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 1.57
- Healthcare median P/E509 names
- 26.0
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.6
- Free cash flow, trailing twelve months
- $180M
- Market capitalisation
- $1.43B
- 3-year revenue growth
- +3.7%
- 3-year free cash flow growth
- +12%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $7.44 |
| Its own P/E history, median | $21.13 |
| Its own P/E history, upper quartile | $40.55 |
| 52-week range | $19.16 – $36.41 |
| Today | $36.41 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore